# Phaxiam Therapeutics (formerly ERYtech Pharma)

Source: https://onco.cc/companies/phaxiam/  
OnCo record `phaxiam` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ERYtech Pharma was a Lyon company that encapsulated the enzyme asparaginase in red blood cells (eryaspase) for leukaemia and pancreatic cancer; after its phase 3 pancreatic trial failed in 2021 it merged into Phaxiam, which now works on bacteriophage therapy.

## Summary

ERYtech Pharma, based in Lyon and listed on Euronext and Nasdaq, developed eryaspase (Graspa), L-asparaginase loaded inside donor red blood cells to prolong its action and reduce hypersensitivity, for acute lymphoblastic leukaemia and metastatic pancreatic cancer. The phase 3 TRYbeCA-1 trial in second-line pancreatic cancer missed its survival endpoint in 2021, and in 2023 the company merged with Pherecydes Pharma to form Phaxiam Therapeutics, which develops phage therapy for antibiotic-resistant infections. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: ERYtech Pharma; Erytech; Phaxiam
- Tags: ctgov-sponsor
- HQ: Lyon
- Type: biotech
- Website: https://www.phaxiam.com

## Sources

- Official website: https://www.phaxiam.com
- ClinicalTrials.gov: trials led by ERYtech Pharma: https://clinicaltrials.gov/search?lead=ERYtech%20Pharma
- Wikipedia: https://en.wikipedia.org/wiki/Erytech_Pharma

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- fronts: [Chemotherapy](https://onco.cc/fronts/chemotherapy/)

---
JSON: https://onco.cc/api/v1/entities/phaxiam.json